Skip to main content
. 2021 Jul 12;12:702636. doi: 10.3389/fimmu.2021.702636

Figure 2.

Figure 2

A workflow for developing and administering cell therapy. CAR T cell-based therapies involve (A) the discovery of disease-associated antigens which can then be used to target the cytotoxic effects of engineered CAR T cells, (B) the isolation and manipulation of patient-derived T cell populations, (C) the infusion of these cells into patients, and (D) downstream monitoring of disease.